Cancer Investigation SCIE

国际简称：CANCER INVEST 参考译名：癌症调查

主要研究方向：医学-肿瘤学非预警期刊审稿周期：约8.5月

《癌症调查》(Cancer Investigation)是一本由Informa Healthcare出版的以医学-肿瘤学为研究特色的国际期刊，发表该领域相关的原创研究文章、评论文章和综述文章，及时报道该领域相关理论、实践和应用学科的最新发现，旨在促进该学科领域科学信息的快速交流。该期刊是一本未开放期刊，近三年没有被列入预警名单。

4区中科院分区
Q3 JCR分区
53 年发文量
1.8 IF影响因子
未开放 是否OA
77 H-index
1983 创刊年份
Bimonthly 出版周期
English 出版语言

Cancer Investigation is one of the most highly regarded and recognized journals in the field of basic and clinical oncology. It is designed to give physicians a comprehensive resource on the current state of progress in the cancer field as well as a broad background of reliable information necessary for effective decision making. In addition to presenting original papers of fundamental significance, it also publishes reviews, essays, specialized presentations of controversies, considerations of new technologies and their applications to specific laboratory problems, discussions of public issues, miniseries on major topics, new and experimental drugs and therapies, and an innovative letters to the editor section. One of the unique features of the journal is its departmentalized editorial sections reporting on more than 30 subject categories covering the broad spectrum of specialized areas that together comprise the field of oncology. Edited by leading physicians and research scientists, these sections make Cancer Investigation the prime resource for clinicians seeking to make sense of the sometimes-overwhelming amount of information available throughout the field. In addition to its peer-reviewed clinical research, the journal also features translational studies that bridge the gap between the laboratory and the clinic.

[ 查看全部 ]

投稿咨询加急咨询

Cancer Investigation期刊信息

ISSN：0735-7907
出版语言：English
是否OA：未开放
E-ISSN：1532-4192
出版地区：UNITED STATES
是否预警：否
出版商：Informa Healthcare
出版周期：Bimonthly
创刊时间：1983
开源占比：0.0535
Gold OA文章占比：7.62%
OA被引用占比：0.0149...
出版国人文章占比：0.16
出版撤稿占比：0
研究类文章占比：83.02%

Cancer Investigation CiteScore评价数据（2024年最新版）

CiteScore

SJR

SNIP

CiteScore 指数

3.8

0.604

0.472

学科类别	分区	排名	百分位
大类：Medicine 小类：Oncology	Q3	217 / 404	46%
大类：Medicine 小类：Cancer Research	Q3	160 / 230	30%

名词解释：CiteScore 是衡量期刊所发表文献的平均受引用次数，是在 Scopus 中衡量期刊影响力的另一个指标。当年CiteScore 的计算依据是期刊最近4年（含计算年度）的被引次数除以该期刊近四年发表的文献数。例如，2022年的 CiteScore 计算方法为：2022年的 CiteScore =2019-2022年收到的对2019-2022年发表的文件的引用数量÷2019-2022年发布的文献数量注：文献类型包括：文章、评论、会议论文、书籍章节和数据论文。

Cancer Investigation中科院评价数据

中科院 2023年12月升级版

Top期刊	综述期刊	大类学科		小类学科
否	否	医学	4区	ONCOLOGY 肿瘤学	4区

中科院 2022年12月升级版

Top期刊	综述期刊	大类学科		小类学科
否	否	医学	4区	ONCOLOGY 肿瘤学	4区

中科院 2021年12月旧的升级版

Top期刊	综述期刊	大类学科		小类学科
否	否	医学	4区	ONCOLOGY 肿瘤学	4区

中科院 2021年12月基础版

Top期刊	综述期刊	大类学科		小类学科
否	否	医学	4区	ONCOLOGY 肿瘤学	4区

中科院 2021年12月升级版

Top期刊	综述期刊	大类学科		小类学科
否	否	医学	4区	ONCOLOGY 肿瘤学	4区

中科院 2020年12月旧的升级版

Top期刊	综述期刊	大类学科		小类学科
否	否	医学	4区	ONCOLOGY 肿瘤学	4区

Cancer Investigation JCR评价数据（2023-2024年最新版）

按JIF指标学科分区	收录子集	分区	排名	百分位
学科：ONCOLOGY	SCIE	Q3	241 / 322	25.3%

按JCI指标学科分区	收录子集	分区	排名	百分位
学科：ONCOLOGY	SCIE	Q4	246 / 322	23.76%

Cancer Investigation历年数据统计

影响因子

中科院分区

Cancer Investigation中国学者发文选摘

1、Trends and Projections of Stomach Cancer Incidence in Hong Kong: A Population-Based Study
Author: Yang, Liping; Sun, Haifeng; Bai, Yan; Sun, Shengzhi; Wu, Xiaoming; Gan, Zhenhai; Du, Jianqiang; Du, Jianfei

Journal: CANCER INVESTIGATION. 2023; Vol. 41, Issue 4, pp. 319-329. DOI: 10.1080/07357907.2022.2126982
2、Tumoral Overexpression of Hepcidin is Associated with Poor Prognosis of Patients with Clear Cell Renal Cell Carcinoma
Author: Qiu, Huizhu; Gu, Guojian; Zuo, Erdong; Cheng, Xu

Journal: CANCER INVESTIGATION. 2023; Vol. 41, Issue 1, pp. 84-92. DOI: 10.1080/07357907.2022.2133775
3、The Prognostic Value of ADAMTS8 and Its Role as a Tumor Suppressor in Breast Cancer
Author: Zhang, Qia; Kanyomse, Quist; Luo, Chenghao; Mo, Qingfan; Zhao, XunPing; Wang, Long; Peng, Weiyan; Ren, Guosheng

Journal: CANCER INVESTIGATION. 2023; Vol. 41, Issue 2, pp. 119-132. DOI: 10.1080/07357907.2022.2128367
4、A DNA Damage Response Related Signature to Predict Prognosis in Patients with Acute Myeloid Leukemia
Author: Wang, Jun; Wu, Jiafei; Wang, Yijing; Wang, Yu; Jiang, Chuanyan; Zou, Mengying; Jin, Xiaokang; Sun, Xiaoran; Zhang, Yu; Ma, Sijia; Wang, Guoqiang; Zhu, Xin; Lu, Huafei; Xu, Chunwei; Wang, Wenxian; Li, Leo; Han, Yusheng; Cai, Shangli; Li, Hui

Journal: CANCER INVESTIGATION. 2023; Vol. 41, Issue 3, pp. 271-283. DOI: 10.1080/07357907.2023.2167209
5、Efficacy and Safety of Bevacizumab for Treating Glioblastoma: A Systematic Review and Meta-Analysis of Phase II and III Randomized Controlled Trials
Author: Xie, Xiaohong; Bao, Shangyi; Zhao, Hong; Li, Liuying; Fu, Xiaojun

Journal: CANCER INVESTIGATION. 2023; Vol. 41, Issue 3, pp. 305-317. DOI: 10.1080/07357907.2023.2174261
6、Poorly Controlled Diabetes Mellitus Increases the Risk of Deaths and Castration-Resistance in Locally Advanced Prostate Cancer Patients
Author: Ma, Cheng; Cui, Di; Han, Bangmin; Ding, Mao; Zhang, Jiahao; Liu, Shiyun; Gao, Yingli; Xia, Shujie

Journal: CANCER INVESTIGATION. 2023; Vol. 41, Issue 4, pp. 345-353. DOI: 10.1080/07357907.2023.2171050
7、Identification and Validation of Molecular Subtype and Prognostic Signature for Bladder Cancer Based on Neutrophil Extracellular Traps
Author: Tu, Yaofen; Mao, Zujie

Journal: CANCER INVESTIGATION. 2023; Vol. 41, Issue 4, pp. 354-368. DOI: 10.1080/07357907.2023.2179063
8、Bioinformatics Identification and Validation of Aging-Related Molecular Subtype and Prognostic Signature in Sarcoma
Author: Hong, Xu; Liu, Hui; Chen, Chu; Lai, Tian; Lin, Jingui

Journal: CANCER INVESTIGATION. 2023; Vol. , Issue , pp. -. DOI: 10.1080/07357907.2023.2209638